Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 2, 1999, Pages 149-171

  Cosson, Valérie F ^a   Fuseau, Eliane ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Data reduction; Migraine; NONMEM; Population analysis; Sumatriptan pharmacokinetics

Indexed keywords

SUMATRIPTAN;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CLUSTER HEADACHE; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; POPULATION; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0032848537     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020601906027     Document Type: Article

References (21)

1. P. A. Fowler, L. F. Lacey, M. Thomas, O. N. Keene, R. J. Tanner, and N. S. Baber. The clinical pharmacology, pharmacokinetics, and metabolism of sumatriptan. Eur. Neurol. 31:291-294 (1991).
2. V. Cosson, J. M. Scherrmann, and E. Fuseau. Population pharmacokinetics of oral sumatriptan. (Abstract). Second meeting of Page, London, UK, June 1994.
3. P. D. Andrew, H. L. Birch, and D. A. Phillpot. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. J. Pharm. Sci. 82:73-76 (1993).
4. S. L. Beal and L. B. Sheiner NONMEM Users Guides, NONMEM Project Group. UCSF, San Francisco, CA, 1992.
5. W. R. Gillespie and P. Veng-Pedersen. A polyexponential deconvolution method. Evaluation of the "gastrointestinal bioavailability" and mean in vivo dissolution time of some ibuprofen dosage forms. J. Pharmacokin. Biopharm. 13:289-307 (1985).
6. P. Veng-Pedersen. An algorithm and computer program for deconvolution in linear pharmacokinetics. J. Pharmacokin. Biopharm. 8:463-481 (1980).
7. P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377-384(1991).
8. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511-528 (1992).
9. S-PLUS, version 3.2, Statistical Science, Seattle, WA, 1994.
10. V. F. Cosson, E. Fuseau, C. Efthymiopoulos, and A. Bye. Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J. Pharmacokin. Biopharm. 25:149-167 (1997).
11. R. C. St-John and N. R. Draper. D-Optimality for regression designs: A review. Technometrics 17:15-23 (1975).
12. C. M. Dixon, D. A. Saynor, P. D. Andrew, J. Oxford, A. Bradbury, and M. H. Tarbit. Disposition of sumatriptan in laboratory animals and humans. Drug Metab. Dispos. 21:761-769 (1993).
13. L. F. Lacey, E. K. Hussey, and P. A. Fowler. Single dose Pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 47:543-548 (1995).
14. V. Cosson, E. Fuseau, and P. Williams. Pharmacokinetic interaction between sumatriptan and MAO inhibitor A: moclobemide (abstract). EFNS, Rome, Italy, October 1996.
15. M. Gibaldi. Biopharmaceutics and Clinical Pharmacokinetics, Lea and Febiger, Philadelphia, 1991.
16. M. Rowland and T. N. Tozer, Clinical Pharmacokinetics. Concepts and Applications, Lea and Febiger, Philadelphia, 1980.
17. R. Boyle, P. O. Behan, and J. A. Sutton. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br. J. Clin. Pharmacol. 30:405-409 (1990).
18. G. N. Volans. Research review migraine and drug absorption. Clin. Pharmacokin. 3:313-318 (1978).
19. L. Ross-Lee, M. J. Eadie, V. Heazelwood, F. Bochner, and J. H. Tyrer. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur. J. Clin. Pharmacol. 24:777-758 (1983).
20. L. A. Pini, M. Bertolotti, T. Trend, and G. Vitale. Disposition of naproxen after oral administration during and between migraine attacks. Headache 33:191-194 (1993).
21. E. K. Hussey, K. H. Donn, M. A. Busch, A. W. Fox, and J. R. Powell. Pharmacokinetics (PK) of oral sumatriptan in migraine patients during an attack and while painfree (abstract). Clin. Pharmacol. Ther. 49:PI-46 (1991).